Publication not explained
This publication has not yet been explained in plain language by the author(s). However, you can still read the publication.
If you are one of the authors, claim this publication so you can create a plain language summary to help more people find, understand and use it.
Featured Image
Read the Original
This page is a summary of: Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective, Journal of Medical Economics, April 2018, Taylor & Francis,
DOI: 10.1080/13696998.2018.1457533.
You can read the full text:
Contributors
The following have contributed to this page
